Jul 06, 2020 09:33 JST
Source: Eisai
|
|
|
Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan
TOKYO, Jul 06, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has launched its in-house-discovered and developed orexin receptor antagonist DAYVIGO? 2.5 mg, 5 mg, 10 mg tablets (lemborexant) for treatment of insomnia in Japan on July 6, 2020. Eisai received marketing and manufacturing approval for this formulation on January 23, 2020, and the product was added to Japan?s National health Insurance drug price list on April 22, 2020.
DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R). DAYVIGO acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm.
The approval of DAYVIGO in Japan is based on findings from two pivotal Phase III studies(1),(2) (SUNRISE 1 and SUNRISE 2) in adult patients with insomnia, as well as evaluation of residual effects including the middle of the night waking, next morning postural stability (falling prediction indicator), and memory through Studies 1063 and 1084.
The SUNRISE 11 clinical trial conducted in North America and Europe utilized objective assessment with overnight measurement through polysomnography, and confirmed statistically significant shortening or improvement of sleep onset latency (primary objective) as well as sleep efficiency and wake after sleep onset (secondary objectives) with DAYVIGO compared to tartrate-sustained-release drug zolpidem (6.25 mg, not yet approved in Japan) and placebo.
The SUNRISE 22 clinical trial, conducted globally including in Japan, evaluated patients subjectively through sleep diaries and confirmed statistically significant improvement in sleep onset latency (primary objective) as well as subjective sleep efficiency and subjective wake after sleep onset (secondary objectives) compared to placebo. Main side effects of DAYVIGO as observed in the two trials were somnolence, headache, dizziness, and fatigue.
Analyses in both studies suggested DAYVIGO was not associated with rebound insomnia, and there was no evidence of withdrawal effects following treatment discontinuation, suggesting it does not produce physical dependence in those taking it for up to one year.
In a special safety study (Study 106)(3), DAYVIGO at 5 mg and 10 mg doses did not cause statistically significant impairment in the next morning driving performance in healthy adult or elderly subjects (compared with placebo). Additional special safety studies (Study 108)(4) evaluated middle-of-the-night safety, next morning postural stability, and memory. The effects of DAYVIGO on next day postural stability and memory were evaluated in two randomized, placebo and active-controlled trials. There were no meaningful differences between DAYVIGO and placebo on next-day postural stability or memory at either dose. While there is a need for caution regarding the potential for middle-of-the-night postural instability as well as attention and memory impairment, no problem-signifying degradation was observed between DAYVIGO- and placebo-administered groups.
In June 2020, DAYVIGO was launched in the U.S. for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. In addition, Eisai submitted a new drug application seeking approval of DAYVIGO in Canada and Australia.
Insomnia is characterized by difficulty falling asleep, staying asleep, or both, despite an adequate opportunity to sleep, which can lead to daytime consequences, such as fatigue, difficulty concentrating, and irritability.(5),(6) Insomnia is one of the most common sleep-wake disorders. Approximately 30% of adults worldwide have symptoms of insomnia.(7),(8) In particular, older adults tend to have a higher prevalence rate with many experiencing insomnia symptoms for months to years. As a result, insomnia causes various social losses, such as long absences and reduced productivity. It can increase the risk of falling in older adults.(9)
Through the launch of DAYVIGO, Eisai will continue to prioritize the provision of appropriate usage and safety information. By providing DAYVIGO as a new option for the treatment of insomnia, Eisai aims for contribution to the restoration of daytime function and recovery for patients with insomnia by delivering an active daytime life through fast sleep onset and good quality sleep.
For more information visit https://www.eisai.com/news/2020/pdf/enews202036pdf.pdf.
Contact:Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech, Healthcare & Pharm
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network. |
Latest Release
Honda to Expand Motorcycle Production Capacity in India by Adding New Motorcycle Production Line to its Second Plant
Mar 19, 2026 18:32 JST
|
Honda WN7 Electric Motorcycle Wins Gold Award at iF DESIGN AWARD 2026
Mar 19, 2026 18:16 JST
| 
Hitachi, The University of Technology Sydney and NTT DATA Sign MoU to Accelerate Green Transformation in Australia
Mar 19, 2026 18:08 JST
| 
MHI Thermal Systems Expands Lineup of Air-to-Water Heat Pumps for the European Market
Mar 19, 2026 15:14 JST
| 
DENSO Invests in Next Core Technologies to Enhance Performance of Electric Vehicles
Mar 19, 2026 14:25 JST
| 
NEC Completes Design of Equipment for Technology Demonstration Satellite Aimed at Creating Japan's First Optical Communication Satellite Constellation
Mar 19, 2026 11:05 JST
| 
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
Mar 19, 2026 10:54 JST
|
Hitachi is recognized as one of the World's Most Ethical Companies(R) for a second consecutive year
Mar 19, 2026 10:41 JST
|
MHI Commends Outstanding Examples of Implementing its New Management Policy "ITO"
Mar 18, 2026 13:09 JST
| 
FILMART and EntertainmentPulse open today
Mar 17, 2026 21:41 JST
| 
TANAKA PRECIOUS METAL GROUP Provides Medals, Commemorative Items, and Trophies as Category Sponsor (Awards Ceremonies) for the LIGA.i Blind Soccer Top League 2025
Mar 17, 2026 21:00 JST
|
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
Mar 17, 2026 19:49 JST
|
Successful Flight Demonstration of Mission Autonomy Developed for Use in Unmanned Aerial Vehicles
Mar 17, 2026 14:11 JST
|
The University of Tokyo and NEC conclude a Strategic Collaboration Agreement to promote a prosperous society where people and AI succeed together
Mar 17, 2026 12:34 JST
|
Hitachi Energy Japan Recognized as a 2026 Health & Productivity Management Outstanding Organization (Large Enterprise Category)
Mar 16, 2026 16:20 JST
| 
Fujitsu Japan and Teikyo University Hospital launch joint proof of concept to build mechanism for data analysis and referred-patient management
Mar 16, 2026 12:55 JST
| 
FWD Group delivers record full year 2025 results with profitable growth, improved capital and cash flow generation
Mar 16, 2026 10:25 JST
|
Mitsubishi Shipbuilding Completes Handover of WAKASHIO MARU Training Ship for National Institute of Technology, Toyama College
Mar 13, 2026 16:01 JST
|
Mitsubishi Heavy Industries to Introduce 10MW-Class Centrifugal Chiller for Next-Generation AI Data Centers in North America
Mar 13, 2026 14:10 JST
| 
Spritzer Sparkling's 'Serikan Raya, Sparkling-kan Suasana' Festive Fusion Message Promotes Togetherness and Tradition with a Light, Modern Twist
Mar 13, 2026 12:45 JST
|
More Latest Release >>
|